Search Results 271-280 of 8412 for Conduction

  1. Publications - Jill M. Huber, M.D. - Mayo Clinic

    MacLeod HM, Culley MR, Huber JM, McNally EM. Lamin A/C truncation in dilated cardiomyopathy with conduction disease. BMC Med Genet. 2003 Jul 10; 4:4. View ...

  2. A Study to Evaluate the Safety and Effectiveness of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer - Mayo Clinic

    Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block); ...

  3. A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) - Mayo Clinic

    * Clinically significant abnormalities detected on ECG of either rhythm or conduction, a Corrected QT interval (QTc) >450 millisecond (msec) or QTc ...

  4. Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) in Patients with Metastatic Pancreatic Adenocarcinoma - Mayo Clinic

    Cardiac conduction abnormalities such as 2nd and 3rd heart-block requiring a pacemaker. Patient with cardiac or abdominal pacemakers or stimulators ...

  5. A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

    Clinically significant ECG abnormalities that require medical attention (i.e., persistent atrioventricular conduction block >first degree, or acute myocardial ...

  6. RLY-2608-201-Ph2 Study of RLY-2608 in PROS and PIK3CA Driven Malformations - Mayo Clinic

    ... conduction, or morphology with resting ECG (e.g., complete left-bundle branch block, 3rd-degree heart block); or clinically significant, uncontrolled ...

  7. Diaphragm Pacing System (DPS) in Participants with Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

    ... conduction studies. Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to ...

  8. A Study to Evaluate the Effect of Olorinab on Gastrointestinal Transit in Patients with Irritable Bowel Syndrome - Mayo Clinic

    ... conduction abnormalities. Clinically significant cardiac history or presence of ECG findings as judged by the Investigator or qualified designee at ...

  9. Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies - Mayo Clinic

    rhythm, conduction or morphology of resting ECG; any factors that increase the risk of QTc prolongation or risk of arrhythmic events such congenital long QT ...

  10. A Study to Evaluate AAV8-human Cocaine Hydrolase to Treat Cocaine Use Disorder - Mayo Clinic

    Show a baseline EKG that demonstrates normal sinus rhythm and conduction without clinically significant abnormalities or arrhythmias. Are willing to return ...